Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
New England Journal of Medicine2012Vol. 367(6), pp. 508–519
Citations Over TimeTop 1% of 2012 papers
Ronald van Vollenhoven, Roy Fleischmann, Stanley Cohen, Eun Bong Lee, Juan A. García Meijide, Sylke Wagner, Šárka Forejtová, Samuel H. Zwillich, David Gruben, Tamás Koncz, Gene V. Wallenstein, Sriram Krishnaswami, John Bradley, Bethanie Wilkinson
Abstract
In patients with rheumatoid arthritis receiving background methotrexate, tofacitinib was significantly superior to placebo and was numerically similar to adalimumab in efficacy. (Funded by Pfizer; ORAL Standard ClinicalTrials.gov number, NCT00853385.).
Related Papers
- → Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis(2018)13 cited
- Tofacitinib (cp-690,550), an oral Janus Kinase Inhibitor: Pooled phase 3 analysis in an Australian Rheumatoid Arthritis Study Population(2012)
- → Long-term safety data for tofacitinib, an oral Janus kinase inhibitor, for the treatment for psoriasis(2018)5 cited
- → Su2090 A Population Pharmacokinetic Model From a Phase 2 Study of Tofacitinib (CP-690,550), an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis(2012)1 cited
- → Tofacitinib: a janus kinase inhibitor for rheumatoid arthritis(2017)1 cited